文献速递泌尿男性生殖肿瘤

前列腺癌短程放疗使用率上升

Increasing Use of Shorter-Course Radiotherapy for Prostate Cancer.
PubMed 文献 · JAMA Oncol · 2023-01-01

这项队列研究利用美国国家癌症数据库2004至2020年数据,纳入313062例接受根治性外照射放疗的局限期前列腺癌患者,分析放疗分割方案的变化趋势。结果显示常规分割比例从76.0%降至36.6%,中度大分割从22.0%升至45.0%,超大分割从2.0%升至18.3%(趋势P均<.001)。多因素分析显示社区癌症项目、医疗补助保险、黑人种族及较高收入中位数与接受短程放疗相关。

要点

  • 2004至2020年,常规分割放疗比例从76.0%降至36.6%,短程方案使用增加(趋势P<.001)。
  • 至2020年,低危组最常见方案为超大分割,中危组为中度大分割。
  • 社区癌症项目(对比学术/研究项目;OR 0.54,95%CI 0.52-0.56)与短程放疗接受相关。

核心结论

  • 2004至2020年前列腺癌短程放疗使用增加,多种健康社会决定因素似乎与短程治疗采用减少相关。
  • 作者认为可能需要调整报销模式以促进超大分割的广泛采用,支持技术购置成本。

研究设计与样本

  • 这项队列研究从美国国家癌症数据库获取数据,该数据库收集超过1500家认证美国机构约72%美国癌症患者的医院登记数据。
  • 纳入2004至2020年诊断的局限期前列腺腺癌并接受根治性外照射放疗的患者,分析于2023年2月至3月进行。
  • 放疗方案分为超大分割(≤7次)、中度大分割(20-30次)和常规分割(31-50次)。

主要发现

  • 共纳入313062例局限期前列腺癌患者(平均[SD]年龄68.8[7.7]岁)。
  • 常规分割比例从2004年76.0%降至2020年36.6%(趋势P<.001);中度大分割从22.0%升至45.0%(趋势P<.001);超大分割从2.0%升至18.3%(趋势P<.001)。
  • 至2020年,低危组最常见放疗方案为超大分割,中危组为中度大分割。
  • 多因素分析:社区癌症项目(对比学术或研究项目;OR 0.54,95%CI 0.52-0.56;P<.001)、医疗补助保险(对比医疗保险;OR 1.49,95%CI 1.41-1.57;P<.001)、黑人种族(对比白人种族;OR 0.90,95%CI 0.87-0.92;P<.001)、较高收入中位数(对比较低收入中位数;OR 1.28,95%CI 1.25-1.31;P<.001)与接受短程放疗相关。

关键数值与推荐

  • 原文未报告指南或共识推荐条款。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Randomized clinical trials have demonstrated the noninferiority of shorter radiotherapy (RT) courses (termed hypofractionation) compared with longer RT courses in patients with localized prostate cancer. Although shorter courses are associated with cost-effectiveness, convenience, and expanded RT access, their adoption remains variable. OBJECTIVE: To identify the current practice patterns of external beam RT for prostate cancer in the US. DESIGN, SETTING, AND PARTICIPANTS: This cohort study obtained data from the National Cancer Database, which collects hospital registry data from more than 1500 accredited US facilities on approximately 72% of US patients with cancer. Patients were included in the sample if they had localized prostate adenocarcinoma that was diagnosed between 2004 and 2020 and underwent external beam RT with curative intent. Analyses were conducted between February and March 2023. EXPOSURES: Radiotherapy schedules, which were categorized as ultrahypofractionation (≤7 fractions), moderate hypofractionation (20-30 fractions), and conventional fractionation (31-50 fractions). MAIN OUTCOMES AND MEASURES: Longitudinal pattern in RT fractionation schedule was the primary outcome. Multivariable logistic regression was performed to evaluate the variables associated with shorter RT courses. Covariables included age, National Comprehensive Cancer Network risk group, rurality, race, facility location, facility type, median income, insurance type or status, and Charlson-Deyo Comorbidity Index. RESULTS: A total of 313 062 patients with localized prostate cancer (mean [SD] age, 68.8 [7.7] years) were included in the analysis. There was a temporal pattern of decline in the proportion of patients who received conventional fractionation, from 76.0% in 2004 to 36.6% in 2020 (P for trend <.001). From 2004 to 2020, use of moderate hypofractionation increased from 22.0% to 45.0% (P for trend <.001), and use of ultrahypofractionation increased from 2.0% to 18.3% (P for trend <.001). By 2020, the most common RT schedule was ultrahypofractionation for patients in the low-risk group and moderate hypofractionation for patients in the intermediate-risk group. On multivariable analysis, treatment at a community cancer program (compared with academic or research program; odds ratio [OR], 0.54 [95% CI, 0.52-0.56]; P < .001), Medicaid insurance (compared with Medicare; OR, 1.49 [95% CI, 1.41-1.57]; P < .001), Black race (compared with White race; OR, 0.90 [95% CI, 0.87-0.92]; P < .001), and higher median income (compared with lower median income; OR, 1.28 [95% CI, 1.25-1.31]; P < .001) were associated with receipt of shorter courses of RT. CONCLUSIONS AND RELEVANCE: Results of this cohort study showed an increase in the use of shorter courses of RT for prostate cancer from 2004 to 2020; a number of social determinants of health appeared to be associated with reduced adoption of shorter treatment courses. Realignment of reimbursement models may be necessary to enable broader adoption of ultrahypofractionation to support technology acquisition costs.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Yu JB, Sun Y, Jia AY, et al. Increasing Use of Shorter-Course Radiotherapy for Prostate Cancer. JAMA Oncol. 2023. PMID: 37796479. doi:10.1001/jamaoncol.2023.4267

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。